NewsBenzinga컬리넌 테라퓨틱스, 재발성 및 난치성 ITP와 온열 자가면역 용혈성 빈혈 성인 환자 대상 글로벌 1b/2a상 임상시험 개시를 위해 FDA 및 호주 치료용품청 승인 획득 컬리넌 테라퓨틱스, 재발성 및 난치성 ITP와 온열 자가면역 용혈성 빈혈 성인 환자 대상 글로벌 1b/2a상 임상시험 개시를 위해 FDA 및 호주 치료용품청 승인 획득 Benzinga 2026.10.27 11:09 (GMT+0) Open on Benzinga Other news Huobi HTX to Open Spot Trading for SOXS, KORU and SNXX on November 17 Duan Yongping Trims Nvidia and Apple in Q3, Exits Alibaba and CRCL, Opens New SpaceX Stake Ethereum Glamsterdam upgrade testing finds bug: some internal payments skipped while transaction succeeds US Says Justice Leads Megaspeed AI-Chip Investigation Soluna Holdings, Inc. (SLNH) Q3 2026 Earnings Call Transcript ‘The Odds Are Almost Zero’: Scott Galloway Doesn’t See Jensen Huang Returning to Nvidia
Ethereum Glamsterdam upgrade testing finds bug: some internal payments skipped while transaction succeeds